- Home
- AD vs TERN Comparison
AD vs TERN Comparison
Compare AD & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AD | TERN |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | 4100 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.8B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AD | TERN |
|---|---|---|
| Price | $46.87 | $49.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $55.00 | $48.60 |
| AVG Volume (30 Days) | 165.8K | ★ 1.9M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 73.21% | N/A |
| EPS Growth | N/A | ★ 11.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $275.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $44.03 | $1.87 |
| 52 Week High | $77.13 | $50.00 |
Technical Indicators
Market Signals| Indicator | AD | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 71.64 |
| Support Level | $46.61 | $38.99 |
| Resistance Level | $50.23 | N/A |
| Average True Range (ATR) | 1.25 | 2.53 |
| MACD | -0.18 | 0.35 |
| Stochastic Oscillator | 31.05 | 89.29 |
Price Performance
Historical ComparisonAbout AD Array Digital Infrastructure Inc.
Array Digital Infrastructure, formerly US Cellular, sold its regional wireless operations serving about 4.4 million customers to T-Mobile in August 2025. The firm has agreed to sell most of its remaining spectrum licenses to Verizon and AT&T; however, it will still retain rights to C-band spectrum in several locations after these deals are closed. Array also owns a 5.5% stake in Verizon Wireless' Los Angeles operations and about 4,400 wireless towers.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.